Results 141 to 150 of about 12,661 (240)

Determinants of T Cell Exhaustion: How Far Back Can We Go?

open access: yesImmunology, EarlyView.
Classical versus Emerging models of CD8+ T Cell Exhaustion. Comparison of the classical ‘Endpoint Model’ (Left), where exhaustion is viewed as a terminal state requiring reversal, versus the emerging ‘Trajectory Model’ (Right). Recent studies suggest exhaustion is a continuous developmental path initiated early in infection or tumuorigenesis ...
Testimony Olumade   +2 more
wiley   +1 more source

Understanding Exosomes in Hair Regeneration

open access: yesPeriodontology 2000, EarlyView.
Abstract Background Alopecia is a prevalent condition correlated with significant psychosocial challenges, while contemporary treatments exhibit variable efficacy, require extended use, and may cause adverse effects. This review aimed to comprehensively assess exosome‐mediated interventions as a novel cell‐free regenerative approach for hair ...
Paras Ahmad   +3 more
wiley   +1 more source

Translating gut microbiome research into therapies for type 1 diabetes

open access: yesExperimental Physiology, EarlyView.
Abstract Type 1 diabetes (T1D) is characterised by the loss of functional pancreatic β‐cells, for which lifelong insulin therapy remains the standard of care. Given that the gut microbiome can influence host health and that shifts in gut microbial profiles have been observed in T1D, growing interest has emerged in the role of the gut microbiome in T1D,
Shanti P. Kok   +2 more
wiley   +1 more source

Cross‐Cancer Profiling of CDH1 Reveals Context‐Dependent EMT Decoupling, Immune Heterogeneity, and Prognostic Variability in Epithelial Cancers

open access: yesComputational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Cadherin 1 (CDH1) encodes E‐cadherin, a key epithelial adhesion molecule traditionally associated with tumor suppression and epithelial–mesenchymal transition (EMT). However, its roles across cancers remain incompletely understood, particularly within multilayer regulatory contexts involving genomic, epigenetic, transcriptional, and immune ...
Md. Abdur Rahman   +2 more
wiley   +1 more source

The Place of Therapeutic Apheresis in Severe Immune‐Related Adverse Events: A Scoping Review of Literature

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 6, December 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet   +36 more
wiley   +1 more source

Treatment‐Associated Type 2/22 Helper T‐Cell States in Dupilumab‐Treated Atopic Dermatitis

open access: yes
Clinical &Experimental Allergy, EarlyView.
Mai Nishimura   +5 more
wiley   +1 more source

Differential FGFR1 copy number status displays unique tumour immune microenvironment in triple‐negative breast cancer

open access: yesThe Journal of Pathology, Volume 270, Issue 4, Page 507-520, December 2026.
Abstract Fibroblast growth factor receptor 1 (FGFR1) amplification, a significant cancer alteration with both prognostic and therapeutic relevance, lacks a standardized definition. The relationship between FGFR1 copy number (CN) variations and tumour microenvironment (TME) characteristics also remains poorly understood.
Yike Gao   +6 more
wiley   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, Volume 13, Issue 62, 9 November 2026.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy